Latest News About Sls Stock

Here’s a concise update on SELLAS Life Sciences Group (SLS) stock as of now.

• Latest news themes: The company has been reporting quarterly results and updates on its SLS009 program, plus progress on the REGAL GPS Phase 3 trial and expansion of SLS009 into new markets, including Europe. This includes positive financing activity and corporate updates from late 2025 into 2026. These developments have driven periodic moves in SLS’s share price amid clinical milestones and funding news. [sources indicating recent press releases and coverage: News aggregators and financial portals tracking SELLAS Life Sciences Group—SLS]

• Stock context: SLS trades on NASDAQ and has been characterized by heightened volatility around clinical milestones, trial updates, and warrant exercises that affect cash runway and dilution. Investors typically react to trial readouts, regulatory updates, and financing news. [general market coverage of SLS dynamics]

• What to watch next:

  • Key catalysts for 2026 include topline data from the SLS009 first-line AML trial (expected Q4 2026) and the REGAL trial event-driven analysis for GPS in AML (80-event threshold). Positive or negative outcomes here could materially impact sentiment and pricing. [clinical trial timelines and milestones reported publicly]
  • European expansion for SLS009 via IMPACT-AML and site initiation in Europe, alongside ongoing US enrollment, could influence near-term activity and investor interest. [partner and enrollment updates from press releases]

If you’d like, I can pull the most recent specific press releases and extract exact dates, trial names, and any financial disclosures to give you a precise, up-to-date snapshot. I can also set up a quick price-and-news tracker for SLS (including daily summaries and any new filings) if you want.